<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01610388</url>
  </required_header>
  <id_info>
    <org_study_id>113376</org_study_id>
    <nct_id>NCT01610388</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Repeat Dose Escalation, First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first time in human (FTIH) study will be the first administration of GSK1322322 as an
      intravenous formulation and will investigate safety, tolerability, and pharmacokinetics in
      healthy subjects. One cohort of subjects will undergo bronchoalveolar lavage (BAL) for
      determination of GSK1322322 concentrations in lung with simultaneous comparison to plasma
      concentrations to evaluate drug penetration in the lung. The study will evaluate the absolute
      bioavailability of an oral tablet formulation as compared to the IV formulation.In addition,
      Amendment 01 will enable the investigation of an improved IV formulation (GSK1322322J
      mesylate salt) in an additional repeat dosing cohort and the supra-therapeutic cohort.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2011</start_date>
  <completion_date type="Actual">January 26, 2012</completion_date>
  <primary_completion_date type="Actual">January 26, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GSK1322322 safety parameters including the number of subjects with adverse events (AEs)</measure>
    <time_frame>Cohort A up to 14 days; Cohort B and C up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 safety parameters including absolute values and changes over time of clinical safety laboratory assessments.</measure>
    <time_frame>Cohort A up to 14 days; Cohort B and C up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 safety parameters including the change from baseline in vital signs (blood pressure (BP) and heart rate)</measure>
    <time_frame>Cohort A up to 14 days; Cohort B and C up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 safety parameters including change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Cohort A up to 14 days; Cohort B and C up to 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 pharmacokinetic parameters (PK) after single oral dose, area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration (AUC(0-t)).</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-∞)).</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose aximum observed concentration (Cmax).</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose time of occurrence of Cmax (tmax).</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose mean residence time (MRTpo)</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose apparent clearance after oral administration (CL/F)</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose apparent volume of distribution after oral administration (Vz/F)</measure>
    <time_frame>Cohorts B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single oral dose terminal phase half-life (t 1/2).</measure>
    <time_frame>cohort B and C on Day -2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose area under the concentration-time curve from zero (pre-dose) to some fixed nominal time (12 hours) (AUC(0-12)).</measure>
    <time_frame>Cohorts A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose area under the concentration-time curve from zero (pre-dose) to some fixed nominal time (24 hours) AUC(0-24)</measure>
    <time_frame>Cohorts A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose AUC(0-t)</measure>
    <time_frame>Cohorts A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose AUC(0-∞).</measure>
    <time_frame>Cohorts A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose Cmax</measure>
    <time_frame>Cohorts A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose mean residence time intravenous (MRTiv)</measure>
    <time_frame>Cohort A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 PK parameters after single IV dose t1/2</measure>
    <time_frame>Cohort A, B, C, D, E on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute bioavailability will be determined by comparing oral AUC(0-∞) to IV AUC(0-∞)</measure>
    <time_frame>Cohort B and C on Day -2 and Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MAT of oral tablet will be determined (=MRTpo-MRTiv)</measure>
    <time_frame>Cohort B and C on Day -2 and Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>After repeated IV doses, pharmacokinetic parameters including Area under the concentration-time curve over the dosing interval (AUC(0-τ))</measure>
    <time_frame>Cohorts A, B, C on Days 3 - 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>After repeated IV doses, pharmacokinetic parameters including Cmax</measure>
    <time_frame>Cohorts A, B, C on Days 3 - 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>After repeated IV doses, pharmacokinetic parameters including CL</measure>
    <time_frame>Cohorts A, B, C on Days 3 - 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GSK1322322 concentrations in BAL obtained in epithelial lining fluid (ELF) and alveolar macrophages (AM) as compared to that in plasma</measure>
    <time_frame>Cohort C Day 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GSK1322322 urine PK parameters: amount excreted (Ae) of unchanged GSK1322322, fraction of the dose excreted in the urine (fe) and renal clearance (CLr) following single dose IV administration from Period 2 and Period 3.</measure>
    <time_frame>cohort B and C on Day 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 6 GSK1322322 AUC(0-τ) compared to AUC(0-12) on Day 1 to evaluate the accumulation ratio following repeat IV administration of GSK1322322.</measure>
    <time_frame>Cohorts A, B, C Day 6 and Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 6 GSK1322322 AUC(0-τ) compared to AUC(0-∞) on Day 1 to evaluate time invariance following repeat IV administration of GSK1322322.</measure>
    <time_frame>Cohorts A, B, C Day 6 and Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1322322 PK parameters: AUC(0-∞) on Day 1 and AUC(0-τ) on Day 6 following IV administration at different doses for the assessment of dose proportionality.</measure>
    <time_frame>Cohorts A, B, C Day1 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome analysis of stool prior to and after exposure to GSK1322322</measure>
    <time_frame>Cohort A, B,C, D, E single sample predose and single sample post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1322322J safety parameters including the number of subjects with adverse events (AEs)</measure>
    <time_frame>Cohort D and E up to 11 days, Cohort F up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1322322J safety parameters including absolute values and changes over time of clinical safety laboratory assessments</measure>
    <time_frame>Cohort D and E up to 11 days; Cohort F up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1322322J safety parameters including the change from baseline in vital signs (blood pressure (BP) and heart rate)</measure>
    <time_frame>Cohort D and E up to 11 days; Cohort F up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1322322J safety parameters including change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Cohort D and E up to 11 days: Cohort F up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Infections, Bacterial</condition>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 60 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 30 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial single 1000mg oral GSK1322322/placebo dose, initial single dose 1000mg IV GSK1322322/placebo followed by BID for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial single 1500mg oral GSK1322322/placebo dose, initial single dose 1500mg IV GSK1322322/placebo followed by BID for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 2000mg IV GSK1322322J/placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 3000mg IV GSK1322322J/placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg IV GSK1322322J/placebo followed by BID for 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500mg IV GSK1322322/placebo</intervention_name>
    <description>500mg IV</description>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_label>Cohort A1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000mg oral GSK1322322/placebo</intervention_name>
    <description>1000mg oral</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000mg IV GSK1322322/placebo</intervention_name>
    <description>1000mg IV</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1500mg oral GSK1322322/placebo dose</intervention_name>
    <description>1500mg oral</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1500mg IV GSK1322322/placebo</intervention_name>
    <description>1500mg IV</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2000mg IV GSK1322322J/placebo</intervention_name>
    <description>2000mg IV</description>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3000mg IV GSK1322322J/placebo</intervention_name>
    <description>3000mg IV</description>
    <arm_group_label>Cohort E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000mg IV GSK1322322J/placebo</intervention_name>
    <description>1000mg IV</description>
    <arm_group_label>Cohort F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by a responsible and experienced physician, based on a medical
             evaluation including [medical history, physical examination, laboratory tests and
             ECGs. A subject with a clinical abnormality or laboratory parameters outside the
             reference range for the population being studied may be included at the discretion of
             the Investigator only if the finding is unlikely to introduce additional risk factors
             and will not interfere with the study procedures.

          -  Male or female between 18 and 65 years of age inclusive, at the time of signing the
             informed consent.

          -  A female subject is eligible to participate if she is of: Non-childbearing potential
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or
             postmenopausal defined as 12 months of spontaneous amenorrhea

          -  Male subjects with female partners of child-bearing potential must agree to use one of
             the contraception methods listed in the protocol. This criterion must be followed from
             the time of the first dose of study medication until the final follow up visit.

          -  Body weight greater than or equal to 50 kilograms and body mass index (BMI) between
             18.5-29.9 (inclusive).

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  QTcB less than 450 millisecond (msec); or QTcB less than 480 msec in subjects with
             Bundle Branch Block on Screening ECG

        Exclusion Criteria:

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Contraindications to bronchoalveolar lavage including hypercapnia greater than 50 mm
             Hg, refractory hypoxemia, reactive airway disease or asthma, unstable angina or acute
             myocardial infarction in the last 6 months, heart failure, and severe hemostatic
             alterations (Cohort C only).

          -  A positive pre-study drug/alcohol screen.

          -  A positive test for HIV antibody.

          -  History of regular alcohol consumption within 6 months of the study

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
             dose of study medication, and within 5 days following discontinuation of GSK1322322
             (for sensitive and narrow therapeutic index CYP3A4 substrates), unless in the opinion
             of the Investigator and GSK Medical Monitor the medication will not interfere with the
             study procedures or compromise subject safety.

          -  Use of antacids, H2 blockers, proton pump inhibitors, vitamins, and iron supplements
             within 7 days prior to the first dose of study medication and for the duration of the
             trial, including follow-up.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  History of sensitivity to medications used in study, ie Atropine, Midazolam, Fentanyl,
             Lidocaine, Codeine (Cohort C only) that, in the opinion of the investigator or GSK
             Medical Monitor, contraindicates their participation.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 milliliters within a 56 day period.

          -  Pregnant females as determined by positive [serum or urine] test at screening or prior
             to dosing.

        Lactating females.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.

          -  Subject is mentally or legally incapacitated.

          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.

          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or
             nicotine-containing products within 6 months prior to screening.

          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice [and/or
             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices] from 7 days prior
             to the first dose of study medication.

          -  Exclusion criteria for screening ECG (a single repeat is allowed for eligibility
             determination): Heart rate: males less than 45 and greater than 100 beats per minute
             (bpm) and females less than 50 and greater than 100bpm. PR interval less than 120 and
             greater than 220msec, QRS duration less than 70 and greater than 120 msec, and QTcB
             greater than 450msec. Evidence of previous myocardial infarction (does not include ST
             segment changes associated with repolarization). Any conduction abnormality (including
             but not specific to left or right complete bundle branch block, AV block [2nd degree
             or higher], Wolf Parkinson White [WPW] syndrome), sinus pauses&gt; 3 seconds,
             non-sustained or sustained ventricular tachycardia (greater than or equal to 3
             consecutive ventricular ectopic beats) or any significant arrhythmia which, in the
             opinion of the principal investigator and GSK medical monitor, will interfere with the
             safety of the individual subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/113376?search=study&amp;study_ids=113376#rs</url>
    <description>Results for study 113376 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>May 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2012</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy subjects</keyword>
  <keyword>double-blind</keyword>
  <keyword>FTIH</keyword>
  <keyword>dose-escalation</keyword>
  <keyword>absolute bioavailability</keyword>
  <keyword>GSK1322322</keyword>
  <keyword>BAL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113376</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

